RecallDepth
Class I Terminated

Cubicin (daptomycin for injection), 500 mg per vial, Single-dose vial, Rx only. Manuf. for: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ 08889, USA. Manuf. by: Baxter Pharmaceuticals LLC., Bloomington, IN 47403, USA, NDC: 67919-011-01

This recall has been terminated (originally issued November 10, 2021).

Company
Merck Sharp & Dohme Corp
Recall Initiated
October 19, 2021
Posted
November 10, 2021
Recall Number
D-0093-2022
Voluntary / Mandated
Voluntary: Firm initiated
Quantity
76,163 vials
Firm Location
Whitehouse Station, NJ, United States
Official Source
View on FDA website ↗

Reason for Recall

Presence of Particulate Matter: Identified as Glass Particles

Distribution

Nationwide within the United States

Lot / Code Info

Lot #: 934778, Exp. Date Jun 2022

More recalls by Merck Sharp & Dohme Corp

View all recalls by this company →

Other recent Class I Drug recalls